title: Efficacy and safety of mometasone furoate nasal spray in nasal polyposis.
abstract: BACKGROUND
  Studies have suggested that topical corticosteroids are effective in the treatment of nasal polyps; however, this has yet to be confirmed in a large, robust clinical trial.
  
  
  OBJECTIVE
  To evaluate the efficacy and safety of mometasone furoate nasal spray (MFNS) for nasal polyposis.
  
  
  METHODS
  A total of 354 subjects with bilateral nasal polyps and clinically significant congestion/obstruction participated in this multinational, randomized, double-blind, placebo-controlled study. Subjects received MFNS 200 microg once or twice daily or placebo for 4 months. Coprimary endpoints were (1) change from baseline to last assessment in physician-evaluated bilateral polyp grade score and (2) change from baseline averaged over month 1 in subject-assessed nasal congestion/obstruction. ANOVA was used for all efficacy endpoints, except for change in bilateral polyp grade score, for which baseline polyp grade was added as a covariate.
  
  
  RESULTS
  Compared with placebo, MFNS 200 microg administered once or twice daily produced significantly greater reductions in bilateral polyp grade score (P < .001, P = .010, respectively) and congestion/obstruction (P = .001, P < .001), as well as improvement in loss of smell (P < .001, P = .036), anterior rhinorrhea (P < .001 for both), and postnasal drip (P < .001, P = .001) over month 1. MFNS 200 microg twice daily was superior to MFNS 200 microg once daily in reducing congestion/obstruction (P = .039), and there were more improvers in the MFNS 200 microg twice daily group (P = .035). MFNS was well tolerated in both groups.
  
  
  CONCLUSIONS
  MFNS 200 mug, once or twice daily, was safe and significantly superior to placebo in reducing polyp grade (size and extent) and improving congestion/obstruction and return of sense of smell. MFNS is an effective medical treatment for nasal polyposis and may reduce or delay the need for surgery.
authors.affiliation: Division of Infectious Diseases, New York Medical College, Valhalla, NY 10595, USA. Catherine_Small@nymc.edu
authors.forename: Catherine Butkus
authors.initials: CB
authors.lastname: Small
authors.forename: Jaime
authors.initials: J
authors.lastname: Hernandez
authors.forename: Antonio
authors.initials: A
authors.lastname: Reyes
authors.forename: Eric
authors.initials: E
authors.lastname: Schenkel
authors.forename: Angela
authors.initials: A
authors.lastname: Damiano
authors.forename: Paul
authors.initials: P
authors.lastname: Stryszak
authors.forename: Heribert
authors.initials: H
authors.lastname: Staudinger
authors.forename: Melvyn
authors.initials: M
authors.lastname: Danzig
mesh_terms: D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000068656:Mometasone Furoate; D009298:Nasal Polyps / Q000188:drug therapy*; D011244:Pregnadienediols / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D011244:Pregnadienediols; D000068656:Mometasone Furoate